Enveric Biosciences (ENVB) Preferred Stock Liabilities (2022)
Enveric Biosciences (ENVB) posted Preferred Stock Liabilities of $527.0 for Q2 2022.
Enveric Biosciences (ENVB) Preferred Stock Liabilities (2022) Analysis & Trends
Enveric Biosciences has reported Preferred Stock Liabilities for 1 years, with the latest figure at $527.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | - |
| 10 | Enveric Biosciences | 5.72 Mn | -2.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 527.00 |